Selegos 50x 5 mg tabs by Medochemie (deprenyl, selegiline) – or Plurimen (Spain) equivalent
“One of the most important anti-aging medicine”
Deprenyl reduces the age-related decline of dopamine, increasing its availability to preserve youthful brain activity
Deprenyl was originally developed as a ‘psychic energizer’, designed to integrate some amphetamine-like brain effects with anti-depressant effects. It has since been shown to protect nerve cells against a wide, and growing, number of neurotoxins, and has been shown to be a neuroprotection/neurorescue agent when nerve cells are exposed to damaging or stressful conditions.
Professor Joseph Knoll proved that Deprenyl improves the availability of dopamine, slows its age-related decline and helps maintain healthy brain cells by acting as a selective MAO-B inhibitor.
Professor Knoll emphasized that the nigrostriatal tract, the tiny DA-using nerve cluster in the basal ganglia (‘old brain’), typically dies off at an average rate of 13% per decade starting around age 45 in humans. This fact sets the human lifespan at about 115 years, since by that age the nigral neuron population would have dropped below 10% of its original number, at which time death ensues even if in all other respects the organism were healthy.
Therefore, human longevity is in-part governed by the rate of dopamine decline. Its support and enhancement means not only longer life, but lucid mental capabilities too. In fact, four different rat studies and one dog study have shown Deprenyl to be an effective life-extension agent.
Based on the sum total of research, Knoll has suggested that if Deprenyl were used from the 40s on, and only modestly lowered the nigrostriatal neuron death rate – say, from 13% to 10% per decade – then the average human lifespan might increase by 15 years.
Deprenyl has become a standard treatment for Parkinson’s disease, and thanks to its aphrodisiac effects, helps to improve sexual function and desire (much more so for men than woman).
Although Parkinson’s disease remains the only FDA approved indication for Deprenyl in the USA, with a number of ongoing clinical studies evaluating its efficacy in Alzheimer’s disease, anecdotal reports from both physicians and patients of dramatic improvement in an impressive number of diseases have been accumulating.
Conditions for which Deprenyl appears to be therapeutic or ameliorative include: cerebral infarction (stroke), hormone inadequacy, amyotrophic lateralizing sclerosis (lou gherig’s disease), fatigue, chronic pain, gastric ulcers, senile dementia, sexual dysfunction, multiple sclerosis, learning difficulties, blepharospasm, hypertension depression and cancer.
Dr. Clyde Reynolds, a clinician who specializes in the metabolic therapy of cancer in Washington State, discovered that cancer patients invariably have imbalances of the neurotransmitters, epinephrine, norepinephrine and serotonin. Dr. Reynolds has found that Deprenyl is highly effective in restoring the normal levels and normal balance of these neurotransmitters. He believes that normalization of the balance of these neurotransmitters is an absolute necessity for the effective treatment of all cancers.
Parkinson and Alzheimer’s disease patients are often treated with very high doses of 20mg daily (usually along with other drugs). Anti-aging doses (dependant on age and condition) are more likely to be 2.5mg to 5mg once, twice or three times a week, or, 1mg to 3mg per day, with regular breaks. Deprenyl tablets are selegiline hydrochloride, which is deprenyl bonded to an in-organic molecule. However, liquid deprenyl citrate (LDC) is selegiline bonded to an organic molecule, one reason why the liquid deprenyl citrate is considered to be superior. This form is generally recognized as the most pure and potent form of deprenyl available. It also allows precise titration for anti-aging purposes, as each ml drop in the bottle is equivalent to 1mg deprenyl citrate. The manufacturer recommends 1mg two times a week for 30 to 35 years olds up to 10mg daily for 80 year olds plus (an age/ dosage list in English is enclosed with order). Ward Dean, M.D., recommends reducing deprenyl doses after several months to lower levels and taking occasional sabbaticals.
Possible gastrointestinal symptoms, such as nausea, heartburn, upset stomach, etc. Some studies have found side effects such as irritability, hyper-excitability, psychomotor agitation and insomnia. These effects are probably due to Deprenyl catecholamine-enhancing effect, over-activating DA/NA neural systems at the expense of calming/sleep-inducing serotonergic systems, so taking magnesium and tryptophan or 5-HTP may suffice to counter these ‘psychic’ effects.